An ongoing phase III multi-cohort trial (IPATunity130) randomizes patients with PI3K/AKT1/PTEN altered metastatic BC to receive paclitaxel plus ipatasertib or placebo as first chemotherapy line. Here, AKT1 is linked to breast cancer.